title: Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia.
abstract: Lactoferrin (LF) is an iron-binding antimicrobial protein present in saliva and gingival crevicular fluids, and it is possibly associated with host defense against oral pathogens, including periodontopathic bacteria. In the present study, we evaluated the in vitro effects of LF-related agents on the growth and biofilm formation of two periodontopathic bacteria, Porphyromonas gingivalis and Prevotella intermedia, which reside as biofilms in the subgingival plaque. The planktonic growth of P. gingivalis and P. intermedia was suppressed for up to 5 h by incubation with >or=130 microg/ml of human LF (hLF), iron-free and iron-saturated bovine LF (apo-bLF and holo-bLF, respectively), and >or=6 microg/ml of bLF-derived antimicrobial peptide lactoferricin B (LFcin B); but those effects were weak after 8 h. The biofilm formation of P. gingivalis and P. intermedia over 24 h was effectively inhibited by lower concentrations (>or=8 microg/ml) of various iron-bound forms (the apo, native, and holo forms) of bLF and hLF but not LFcin B. A preformed biofilm of P. gingivalis and P. intermedia was also reduced by incubation with various iron-bound bLFs, hLF, and LFcin B for 5 h. In an examination of the effectiveness of native bLF when it was used in combination with four antibiotics, it was found that treatment with ciprofloxacin, clarithromycin, and minocycline in combination with native bLF for 24 h reduced the amount of a preformed biofilm of P. gingivalis compared with the level of reduction achieved with each agent alone. These results demonstrate the antibiofilm activity of LF with lower iron dependency against P. gingivalis and P. intermedia and the potential usefulness of LF for the prevention and treatment of periodontal diseases and as adjunct therapy for periodontal diseases.
authors.affiliation: Food Science & Technology Institute, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan. h_wakaby@morinagamilk.co.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Wakabayashi
authors.forename: Koji
authors.initials: K
authors.lastname: Yamauchi
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Yaeshima
authors.forename: Keiji
authors.initials: K
authors.lastname: Iwatsuki
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Yoshie
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development*; D002939:Ciprofloxacin / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology; D006801:Humans; D007781:Lactoferrin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000494:pharmacology; D016966:Porphyromonas gingivalis / Q000187:drug effects* / Q000254:growth & development*; D018713:Prevotella intermedia / Q000187:drug effects* / Q000254:growth & development*
chemical_list: D000890:Anti-Infective Agents; C082171:lactoferricin B; D002939:Ciprofloxacin; D007781:Lactoferrin; D008911:Minocycline; D017291:Clarithromycin